AstraZeneca/Sanofi’s Nirsevimab Nears US FDA Approval After Overwhelmingly Positive Adcomm

 
• By Derrick Gingery
FDA AMDAC meeting screenshot
Advisory committee members voted that the benefits outweigh the risks of the proposed RSV prevention treatment nirsevimab. • Source: screenshot

More from US FDA Performance Tracker

More from Regulatory Trackers